16th Sep 2009 17:25
|
For immediate release |
16 September 2009 |
("Abcam" or "the Company")
Director's Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that on 16 September 2009 Mike Redmond, a Non-Executive Director of the Company, purchased 15,000 ordinary shares of 1 pence each in the Company at a price of 802p per ordinary share. Following this transaction Mr Redmond's total beneficial interest in the Company is 15,000 ordinary shares representing approximately 0.04 per cent. of the current issued share capital of the Company.
In addition, the Company was notified today that on 16 September 2009 Peter Keen, a Non-Executive Director of the Company, exercised share options over 60,000 ordinary shares of 1 pence each in the Company at an exercise price of 150p per share. Mr Keen also simultaneously sold 35,157 of these shares at a price of 800p per ordinary share. Following this transaction, Mr Keen's total beneficial interest in the Company is 33,825 ordinary shares representing approximately 0.1 per cent. of the current issued share capital of the Company.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeffrey Iliffe, Chief Financial Officer |
|
|
Numis Securities |
+ 44 (0) 20 7260 1000 |
|
Michael Meade / Nick Westlake - Nominated Adviser |
|
|
James Black - Corporate Broking |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Mary-Jane Johnson / Stasa Filiplic |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA and Tokyo, Japan. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 52,000 products, most of which are antibodies, from over 250 suppliers and employs 237 staff in its three operating companies.
Related Shares:
ABC.L